Biomarkers for immunotherapy in digestive and gynecological cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks for new markers in the blood or tumor that could predict how well immunotherapies work for advanced digestive and gynecological cancers. It includes people getting immunotherapy, chemotherapy, or targeted therapy, and also those with certain liver or abdominal metastases that can be surgically removed after chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a type of advanced digestive or gynecological cancer (like liver, bile duct, stomach, colorectal, or ovarian)
- You are either receiving or are eligible for immunotherapy, chemotherapy, or targeted therapy (depending on your cancer type)
- If you have colorectal cancer spread to the liver or ovarian cancer spread to the abdomen, it must be possible to remove it with surgery after chemotherapy
- You have a life expectancy of more than 6 months, and you are in generally good health (ECOG score 0 to 2 – meaning you can take care of yourself)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
This study looks at how well immunotherapy works for advanced or recurrent endometrial and cervical cancer by checking certain markers in your blood and tissue. It aims to find out which patients might benefit most from this treatment.
This trial tests an immunotherapy that uses your own immune cells to fight advanced digestive-system cancers. It aims to see if this treatment is safe and if it can help shrink tumors or slow their growth.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study looks at how tumors in the digestive system interact with the body’s immune system and the surrounding environment. Results may help improve understanding of these cancers and guide future treatments.
This study looks at blood samples from people with blood cancers to find markers that might predict how well immunotherapy will work. The goal is to help doctors choose the right treatment for each person.
Hear when a new Advanced Digestive Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.